64304
document
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies . Hypertension after treatment with vascular endothelial growth factor ( VEGF ) receptor inhibitors is associated with superior treatment outcomes for advanced cancer patients . To determine whether increased sorafenib doses cause incremental increases in blood pressure ( BP ) , we measured 12-h ambulatory BP in 41 normotensive advanced solid tumor patients in a randomized dose-escalation study . After 7 days ' treatment ( 400 mg b.i.d . ) , mean diastolic BP ( DBP ) increased in both study groups . After dose escalation , group A ( 400 mg t.i.d . ) had marginally significant further increase in 12-h mean DBP ( P = 0.053 ) , but group B ( 600 mg b.i.d . ) did not achieve statistically significant increases ( P = 0.25 ) . Within groups , individuals varied in BP response to sorafenib dose escalation , but these differences did not correlate with changes in steady-state plasma sorafenib concentrations . These findings in normotensive patients suggest BP is a complex pharmacodynamic biomarker of VEGF inhibition . Patients have intrinsic differences in sensitivity to sorafenib 's BP-elevating effects .
64305
Intervention_Pharmacological
Sorafenib
64306
Intervention_Pharmacological
sorafenib
64307
Outcome_Physical
blood pressure ( BP )
64308
Participant_Condition
normotensive
64309
Participant_Condition
advanced malignancies
64310
Participant_Condition
advanced cancer patients
64311
Participant_Sample-size
41
64312
Participant_Condition
normotensive advanced solid tumor patients